Rolling Out8h
These new remedies works better in pain management
Discover how innovative physical therapy, smart medications, nutrition strategies and mind-body techniques are transforming ...
Clinical Trials Arena on MSN2d
Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.
Business Wire3d
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Trea…
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...
Clinical Pain Advisor2d
FDA Fast Tracks Investigational Nonopioid Treatment for Acute Pain
The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.
BioPharma Dive2d
Vertex’s new pain drug gets first coverage nod from major insurer
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
Applied Clinical Trials Online3d
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...
Fierce Biotech3d
Tris' next-gen pain drug completes trio of clinical wins, setting up push to FDA
Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...
Medindia10d
Stronger Opioids, Stronger Pain? A Shift in Perioperative Pain Care
Opioids like sufentanil and remifentanil during surgery may worsen post-surgery pain, highlighting the need for a review of ...
Vertex Pharma drops as UnitedHealth offers Tier 3 coverage for new pain medicine
Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...
2 Minute Medicine5d
Vertex: non-opioid pain reliever Journavx shows success in post operative pain control
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...